Siga Technologie Stock Price, News & Analysis

SIGA Technologies, Inc. (SIGA) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) supports the Marketing Authorisation Application for oral tecovirimat, which treats smallpox and related diseases. This recommendation facilitates potential sales across EU member states, Norway, Iceland, and Liechtenstein, with SIGA targeting EMA approval by Q1 2022. SIGA's strategy aims to enhance global access to tecovirimat amid rising infectious disease threats, reflecting its commitment to health security.

SIGA Technologies, Inc. (SIGA) reported financial results for the third quarter of 2021, showing total revenues of $4.8 million, a significant improvement from a net loss of $3.1 million in Q3 2020. For the first nine months, revenues reached $18.3 million, compared to $87.2 million for the same period in 2020. The company is set to deliver approximately $113 million of oral TPOXX® to the U.S. government in Q4 2021. SIGA has repurchased about 1.1 million shares for $7.1 million in Q3 2021, totaling approximately $49 million in its current repurchase program.

SIGA Technologies (NASDAQ: SIGA) announced a conference call on November 4, 2021, at 4:30 P.M. ET, to provide a business update. The call will include CEO Dr. Phil Gomez and CFO Daniel Luckshire, and will be accessible via phone or live webcast. SIGA focuses on health security, primarily through its lead product, TPOXX® (tecovirimat), an antiviral for smallpox treatment, with approximate government orders of $705 million for preparedness. The company emphasizes its role in biodefense and emerging infectious diseases.

SIGA Technologies, Inc. (SIGA) announced the exercise of a procurement option under its BARDA contract, facilitating the delivery of oral TPOXX® treatment courses valued at approximately $112.5 million to the U.S. government. This order is part of a total of approximately $123 million in orders received for 2021, emphasizing the significance of smallpox preparedness. TPOXX® is an antiviral drug for smallpox treatment, with the U.S. government maintaining a stockpile for national health security.

On September 8, 2021, SIGA Technologies CEO, Dr. Phil Gomez, will speak at the NCT USA conference in Baltimore. His presentation focuses on the development of antiviral drugs for epidemic preparedness, emphasizing the critical role of TPOXX^® in combating smallpox. Dr. Gomez highlights the importance of robust stockpiling of antiviral drugs to manage future outbreaks effectively. SIGA has procured approximately $705 million of TPOXX for U.S. Government stockpiles, with an additional $300 million in options remaining for future procurement.

SIGA Technologies, Inc. (SIGA) reported second-quarter revenues of $8.7 million, driven by $7 million in international sales of oral TPOXX® to Canada. This marks a continued growth trajectory from $3 million in the previous quarter. However, net income was just $0.2 million with a diluted loss per share of $0.00. The company also announced a new share repurchase program of up to $50 million. The FDA submission for intravenous TPOXX® could expand the market, but the timeline for completion is currently uncertain due to COVID-19 impacts.

On July 29, 2021, SIGA Technologies, Inc. (SIGA) announced a webcast and conference call for August 5, 2021, at 4:30 P.M. ET, featuring CEO Dr. Phil Gomez and CFO Daniel Luckshire. The meeting aims to provide a business update. SIGA focuses on health security, primarily through its lead product, TPOXX^®, which is FDA-approved for treating smallpox. The U.S. government maintains a stockpile of 1.7 million courses of TPOXX^®. Additionally, SIGA signed a contract worth over $600 million with BARDA in September 2018 for its development.

SIGA Technologies (SIGA) has partnered with Oxford University to provide TPOXX® (tecovirimat) for treating monkeypox in the Central African Republic (CAR). This collaboration will see SIGA supplying up to 500 courses of the drug at no cost, while the Institut Pasteur of Bangui will coordinate the study. The Ministry of Health in CAR will administer TPOXX to patients affected by monkeypox. SIGA is also pursuing regulatory approval from the European Medicines Agency (EMA) to include monkeypox in the drug's label indication, anticipating approval in late 2021 or early 2022.

SIGA Technologies, Inc. (SIGA) announced the delivery of TPOXX® (tecovirimat) to Liverpool University Hospitals, UK, for compassionate treatment of a monkeypox patient. TPOXX is FDA-approved for treating smallpox and has been used in various compassionate cases, including cowpox. SIGA is expanding its regulatory approvals in the EU and Canada for broader indications to treat orthopox viruses. TPOXX is stockpiled by the U.S. Government, with an aim to provide essential health security against emerging infectious diseases.